Pooled analysis of three randomized, double-blind, placebo controlled trials with rimonabant for smoking cessation.

ABSTRACT: Despite the withdrawal of CB₁ antagonists, such as rimonabant, from the market and from active clinical development because of concerns about their side effect profiles, research suggests that the endocannabinoid system may play an important role in modulating nicotine's effects. We report the combined results, using a pooled analysis, of three previously unpublished trials assessing rimonabant as a smoking cessation pharmacotherapy conducted between 2002 and 2004. Smokers (n = 2097) motivated to quit were enrolled in three randomized, double-blind, placebo-controlled trials, STRATUS EU, US, and META, which consisted of a 10-week treatment period with either rimonabant 20 mg (n = 789), 5 mg (n = 518; used in only two of the three studies), or placebo (n = 790), in conjunction wi

SUBMITTER: Robinson JD 

PROVIDER: S-EPMC5912319 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature